Evidence map›Paper›PMID 34593269›Full record

ArticleVaccine2022

National introduction of HPV vaccination in Senegal-Successes, challenges, and lessons learned.

Rebecca M Casey, Nedghie Adrien, Ousseynou Badiane, Aliou Diallo, Jerlie Loko Roka, Timothy Brennan, Reena Doshi, Julie Garon, Anagha Loharikar

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Rebecca M CaseyCDC Foundation, Atlanta, GA, USA; Centers for Disease Control and Prevention, Atlanta, USA. Electronic address: dr.rmcasey@gmail.com.
Nedghie AdrienCDC Foundation, Atlanta, GA, USA.
Ousseynou BadianeExpanded Program on Immunization, Senegal.
Aliou DialloWorld Health Organization, Senegal Country Office, Dakar, Senegal.
Jerlie Loko RokaCenters for Disease Control and Prevention, Dakar, Senegal.
Timothy BrennanCDC Foundation, Atlanta, GA, USA.
Reena DoshiCenters for Disease Control and Prevention, Atlanta, USA.
Julie GaronCenters for Disease Control and Prevention, Atlanta, USA.
Anagha LoharikarCenters for Disease Control and Prevention, Atlanta, USA.
Centers for Disease Control and Prevention · USCDC Foundation · USEnvironment and Development Action Third World · SN

Funding

Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

Following successful school-based demonstration programs in 2014-2016, the human papillomavirus (HPV) vaccine was introduced nationwide in Senegal for 9-year-old girls in 2018, using a routine service delivery strategy at health facilities, schools, and other outreach sites. We reviewed the HPV vaccine introduction in Senegal to understand the successes, challenges, and lessons learned. Focusing on three key domains (program decision-making, planning, and implementation), we conducted ten semi-structured interviews during 2019-2020 with purposively selected national-level stakeholders (government, expert advisory committee, key technical and implementation partners) and comprehensive desk reviews of country documents on HPV vaccine introduction. Due to the global HPV vaccine shortage, the introduction was limited to a single-age cohort; therefore, 9-year-old girls were chosen. This strategy enabled Senegal to potentially reach more girls in primary education because school enrolment rates decline thereafter. Vaccination through routine delivery platforms (i.e., health facility, school-based, and community outreach) was perceived to be more cost-effective than a campaign approach. High-level political commitment and collaborations between immunization and education partners were frequently cited by key informants as reasons for a successful vaccine introduction. All key informants reported that the health care worker (HCW) strike, rumors, and vaccine hesitancy negatively impacted the introduction. Other challenges noted included insufficient information on attitudes towards HPV vaccination among HCWs, teachers, and community members. Senegal successfully introduced HPV vaccine into the national immunization schedule, using a routine delivery strategy. Strong leadership and a multi-sectoral approach likely contributed to this success. To build sustainability of the HPV vaccination program in the future, it is important to improve the understanding and engagement among all stakeholders, including HCWs and community members, and to strengthen and innovate communication and crisis management strategies. To better understand the efficiency and effectiveness of Senegal's vaccination strategy, additional assessments of the operational costs and coverage achieved are needed.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsChildFemaleHumansImmunization ProgramsSenegalVaccinationPapillomavirus VaccinesHuman papillomavirusSenegalVaccinationVaccine introduction

Identifiers

PMID34593269
PMCPMC10662429
OpenAlexW3203524833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.